Outcome of children with relapsed high-risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem cell transplantation. (5th February 2022)

• Record Type: Journal Article
• Authors: Hara, Junichi; Nitani, Chika; Shichino, Hiroyuki; Kuroda, Tatsuo; Hishiki, Tomoro; Soejima, Toshinori; Mori, Tetsuya; Matsumoto, Kimikazu; Sasahara, Yoji; Iehara, Tomoko; Miyamura, Takako; Kosaka, Yoshiyuki; Takimoto, Tetsuya; Nakagawara, Akira; Tajiri, Tatsuro
• Is Part Of: Japanese journal of clinical oncology. Volume 52:Number 5(2022)
• Page Start: 486
• Page End: 492
• Publication Date: 2022-02-05
• Subjects: relapse -- allogeneic hematopoietic stem cell transplantation -- neuroblastoma; Oncology -- Periodicals; Cancer -- Periodicals; 616.994005
• DOI: 10.1093/jjco/hyac007
• Languages: English
• ISSNs: 0368-2811

Abstract

Abstract: Background: In Japan, allogeneic hematopoietic stem cell transplantation is widely performed for recurrent neuroblastomas. This retrospective study aimed to investigate the prognosis of recurrent neuroblastoma in Japan and explore the effectiveness of allogeneic hematopoietic stem cell transplantation. Methods: Clinical characteristics and data on the treatment of patients with high-risk neuroblastoma who experienced first progression between 2003 and 2010 after attaining complete remission or partial remission were collected from hospitals participating in the Japanese Neuroblastoma Research Group. Results: Data from 61 patients who fulfilled these criteria were collected. The median interval from disease onset to first progression was 19 months (range, 7–65 months), whereas the median observation time of the surviving patients was 18 months (range, 1–69 months). All patients were treated with chemotherapy, where 22 and 3 patients received allogeneic and autologous hematopoietic stem cell transplantation, respectively. Seven patients were alive in second complete remission, and 39 died, including two in complete remission. The 3-year progression-free survival and overall survival rates were 15.3% (SE: 6.1%) and 16.9% (SE: 6.5%), respectively. For patients with allogeneic hematopoietic stem cell transplantation, the 3-year progression-free survival and overall survival were 28.3% (standard error, 12.0%) and 24.3% (standard error, 11.5%), respectively, and for patients without allogeneic hematopoietic stem cell transplantation, the 3-year progression-free survival and overall survival were 6.0% (standard error 5.5%) and 12.0% (standard error 7.6%), respectively. The duration of initial remission (≥ 18 months) and implementation of allogeneic hematopoietic stem cell transplantation were independently predictive of progression-free survival ( P = 0.002 and P = 0.017), whereas for overall survival, only allogeneic hematopoietic stem cell transplantation was predictive ( P = 0.012). Conclusion: Although allogeneic hematopoietic stem cell transplantation contributed to some improvement in prognosis, it was insufficient. Abstract : Although allogeneic hematopoietic stem cell transplantation contributed to some improvement in the prognosis of relapsed high-risk neuroblastoma, it was insufficient. In the future, immunotherapies such as targeting GD2 will be the main treatment.